Supplementary Information (PDF 638 kb) Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made
Through our platform, you can conveniently access cutting-edge GLP-1 treatments
J.WainsteinJ.JiangH.RobertsonK
Insulin-like growth factor receptor signaling regulates working memory, mitochondrial metabolism, and amyloid-beta uptake in astrocytes
Dettagli del Corso A PRE 6 S Riferimento A PRE 6 S Scarica il modulo qui sotto e inserisci il codice del corso nellapposita casella per partecipare

Your GP or prescriber should be informed of: All current medicines , including over-the-counter supplements and herbal remedies, to assess potential interactions particularly for medicines with a narrow therapeutic index Any history of liver, kidney, gastrointestinal, or pancreatic conditions , which may influence the safety of lipotropic agents or GLP-1-based therapies Diabetes or pre-diabetes , given the glucose-modulating effects of retatrutide Previous adverse reactions to injectable preparations or weight management treatments The following groups should not use retatrutide or Lipo C injections outside approved clinical trials, and should discuss their options carefully with a clinician: People who are pregnant, breastfeeding, or planning to conceive Adolescents and young people under 18 years of age People with significant hepatic or renal impairment If you are approached by a private clinic offering retatrutide or Lipo C injections, ask for full documentation of the product's regulatory status, the prescriber's qualifications, and the clinical rationale for the proposed treatment plan
